A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
- Conditions
- Hypertension
- Registration Number
- NCT00240448
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg/hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg/hydrochlorothiazide 25 mg \[Diovan HCT\] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1109
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in mean seated trough cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period
- Secondary Outcome Measures
Name Time Method Percentage of responders based on change from baseline in cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period
Trial Locations
- Locations (22)
Boehringer Ingelheim Investigational Site
🇺🇸Milwaukee, Wisconsin, United States
Memorial Research Medical Clinic
🇺🇸Long Beach, California, United States
Clinical Trials Research
🇺🇸Roseville, California, United States
Clinical Research Consultants, Inc.
🇺🇸Trumbull, Connecticut, United States
Christopher Chappel, MD
🇺🇸Kissimmee, Florida, United States
Orlando Clinical Research Center
🇺🇸Orlando, Florida, United States
Attention: Larry I. Gilderman, D.O.
🇺🇸Pembroke Pines, Florida, United States
Grady Memorial Hospital
🇺🇸Atlanta, Georgia, United States
Treasure Valley Cardiology
🇺🇸Boise, Idaho, United States
Cedar-Crosse Research Center
🇺🇸Chicago, Illinois, United States
Scroll for more (12 remaining)Boehringer Ingelheim Investigational Site🇺🇸Milwaukee, Wisconsin, United States